Health

The size of the market for treatable mental health disorders is currently $300 billion in the U.S. and is expected to grow over the next five years. An opportunity exists for clinical-stage companies to commercialize their operations with alternative treatment methods to fill this need. The following article describes the commercialization developments, market capitalizations, and price performances of 6 companies in the industry. [more]

The six main constituents were down 26.9% in April and are now down 54.2% YTD. The next four constituents were down 23.3% in April and are now down 47.1% YTD. [more]

The munKNEE Pure-Play Plant-Based Food Stocks Index is down 17.4% so far this month and is now down 45.9% YTD and down 77.5% from its peak in 2021. [more]

mCloud Technologies, a leading AI-powered physical asset management solution provider, announced financial results for the second quarter ended June 30, 2021. Revenues increased by 44% compared to Q2/2020 and added 1,019 new connected assets to its managed portfolio. [more]

Zoom entered into two definitive agreements to acquire Five9, a leading contact center software based on cloud technology, for $14.7B and Kites, which provides real-time Machine Translation solutions. [more]

Patients hospitalized by COVID-19 that end up in intensive care are likely to be diagnosed with acute kidney injury (AKI), face few treatment options and a high mortality rate, but a new potential option is on the way. [more]

In a few short months, ScreenPro Security has emerged as a one-stop shop for Canadian COVID-19 testing and international travelers needing digital COVID-19 passport capabilities. [more]

Investors inject cash into Eupraxia Pharmaceuticals during its IPO on the TSX. The funds will be used to support clinical trials of their leading knee osteoarthritis treatment. Eupraxia’s polymer technology promises to flatten the drug-dose curve, providing long-term pain relief (up to 6 months) with fewer side effects. [more]